Citigroup
CGTX icon

Citigroup’s Cognition Therapeutics CGTX Stock Holding History

Citigroup’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.76K Buy
+7,620
New +$9.02K ﹤0.01% 5256

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Citigroup's CGTX Position: Q2 2026 in Review

Citigroup opened a new position in Cognition Therapeutics (CGTX) in Q2 2026: 7,620 shares worth $8.76K. The stake represents ﹤0.01% of the portfolio and ranks #5256 among its holdings.

66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Citigroup held 7,620 shares of Cognition Therapeutics worth $8.76K as of Q2 2026.
  • Cognition Therapeutics was a new Citigroup position in Q2 2026.
  • Cognition Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5256 holding.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.